MHRA Explains Entry Criteria for UK's New Innovative Medicines Pathway
‘Innovation Passport’ Will Be Gateway To Targeted Development
A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.